

TNF alpha Protein, Human, Recombinant (aa 77-233, His)

General Information

Synonyms:	TNF- α ;TNF- α ;Tumor Necrosis Factor;TNFA;Tumor Necrosis Factor Ligand Superfamily Member 2;TNF α ;Cachectin;TNF;TNFSF2;TNF-Alpha
Protein Construction:	Val77-Leu233
Species:	Human
Expression Host:	E. coli
Accession:	P01375
Molecular Weight:	16 KDa (reducing condition)
AA Sequence:	Val77-Leu233

QC Testing

Biological Activity:	Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is 10-40 pg/ml. (QC verified)
Purity:	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Endotoxin:	< 0.1 ng/ μ g (1 EU/ μ g) as determined by LAL test.
Formulation:	Lyophilized from a solution filtered through a 0.22 μ m filter, containing 20 mM Tris-HCl, 150 mM NaCl, pH 8.0.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μ g/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months.

Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor Necrosis Factor- α (TNF- α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF- α while cells that express CD8 secrete little or no TNF- α . Synthesis of TNF- α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF- α has been limited by the proinflammatory side effects

such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF- α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF- α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF- α , which binds to both murine TNF receptors. Based on these results, many TNF- α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF- α High Active Mutant differs from the wild-type by amino acid substitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481